CIAM
TCRX icon

Caitong International Asset Management’s TScan Therapeutics TCRX Stock Holding History

Caitong International Asset Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Sell
1
-1
-50% -$1 ﹤0.01% 2920
2026
Q1 		$2 Buy
+2
New +$2 ﹤0.01% 2435

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Caitong International Asset Management's TCRX Position: Q2 2026 in Review

Caitong International Asset Management reduced its TScan Therapeutics (TCRX) stake by 50% in Q2 2026, selling an estimated $1 and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #2920.

Caitong International Asset Management first reported a position in TCRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2 in Q1 2026. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Caitong International Asset Management held 1 share of TScan Therapeutics worth $1 as of Q2 2026.
  • Caitong International Asset Management sold 1 TScan Therapeutics share in Q2 2026, an estimated $1.
  • TScan Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2920 holding.
  • Caitong International Asset Management first reported a position in TScan Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Caitong International Asset Management's TScan Therapeutics position peaked at $2 in Q1 2026.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.